# A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

> **NCT00741403** · PHASE1 · COMPLETED · sponsor: **Cornerstone Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer
- Lymphoma
- Solid Tumors
- Advanced Malignancies

## Interventions

- **DRUG:** CPI-613

## Key facts

- **NCT ID:** NCT00741403
- **Lead sponsor:** Cornerstone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00741403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00741403, "A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00741403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*